Regenerative Medicine

TeVido BioDevices Announces Availability of TruPigment™ for use in restoring lost skin color | PRWeb | 9/16/2019

TeVido BioDevices Announces Availability of TruPigment™ for use in restoring lost skin color Share Article TruPigment™ enables physicians to provide skin cell transplants without making costly investment in equipment and specialized skills. AUSTIN, Texas TeVido BioDevices (TeVido), a leader in regenerative medicine for repairing loss of pigmentation, today announced commercial availability of their lead product TruPigment™(autologous non-cultured epidermal cell suspension). TeVido processes a sample of a patient’s healthy …

Tissue Genesis’ Icellator X Delivers Results in First Clinical Application | 9/16/2019

… Genesis, a leading developer of cell therapy processing systems, announced that an initial group of patients was successfully treated in the first clinical application of its Icellator X technology at the Okyanos Center for Regenerative Medicine in Freeport, Bahamas. The new fully enclosed and automated system generated a higher yield of stem cells from adipose (fat) tissue than had been previously possible.The patients received stem cell therapy at the Okyanos …

Follow Regenerative Medicine:    

Contrasting Organogenesis (NASDAQ:ORGO) & Soligenix (NASDAQ:SNGX) - American Banking News | 9/16/2019

Soligenix has lower revenue, but higher earnings than Organogenesis. Summary Organogenesis beats Soligenix on 6 of the 10 factors compared between the two stocks. Organogenesis Company Profile Organogenesis Holdings Inc., a regenerative medicine company, focuses on the development, manufacture, and commercialization of solutions for the advanced wound care, and surgical and sports medicine markets primarily in the United States. The company’s advanced wound care products include Apligraf for the treatment …

JFB, Vol. 10, Pages 42: Effect of Process Parameters on the Initial Burst Release of Protein-Loaded Alginate Nanospheres | 9/16/2019

The controlled release or delivery of proteins encapsulated in micro/nanospheres is an emerging strategy in regenerative medicine. For this, micro/nanospheres made from alginate have drawn considerable attention for the use as a protein delivery device because of their mild fabrication process, inert nature, non-toxicity and biocompatibility. Though promising, one key issue associated with using alginate micro/nanospheres is the burst release of encapsulated protein at the beginning …

BioLife Solutions Announces New evo® Cold Chain Customers | Benzinga | 9/16/2019

… industry. Mike Rice , BioLife Solutions CEO, remarked, “By partnering with the leading specialty couriers and leveraging their worldwide sales, marketing and operations footprint, we continue to drive adoption of the evo system in the regenerative medicine space. We expect to capture a significant share of early stage cell and gene therapy companies as evo customers. In the coming quarters, we also expect to announce the complete or partial migration of …

Pluristem Therapeutics Recaps Key Opinion Leader Call Reviewing Hematological Programs | Globe Newswire | 9/16/2019

… versus current standards of care, with the goal of executing a full contract once the study is completed” HAIFA, Israel, Sept. 16, 2019 (GLOBE NEWSWIRE) – Pluristem Therapeutics Inc . (Nasdaq: PSTI ) (TASE: PSTI ) , a leading regenerative medicine company developing novel placenta-based cell therapy products, today provided a recap of the Key Opinion Leader call hosted by the company this morning to review unmet medical needs in acute radiation syndrome (ARS …

Biotechnology Market is Estimated to be Valued $727.1 Billion By 2025: Grand View Research, Inc | The Wapakoneta Daily News | 9/16/2019

… a new report by Grand View Research, Inc. The emergence of certain key themes in the biotechnology market is expected to drive growth in this industry to a lucrative extent. These key themes include regenerative medicine and genetics in diagnostics. Presence of a plethora of companies focusing on the development of regenerative therapies is anticipated to drive sector growth through to 2025. Technological advancements pertaining to the penetration of artificial …

Royal Biologics announces the U.S. commercial launch of Maxx-Ultra Cord | 9/16/2019

Royal Biologics, a leading manufacturer and distributor of orthobiologic and regenerative medicine solutions today has announced the U.S. commercial launch of Maxx™ Ultra Cord, a maximum natural thickness allograft derived from umbilical cord. Maxx™Ultra Cord provides an alternative from traditional placental layer membrane allografts by providing up to 8X thicker membrane options that can be sutured and offers excellent handling characteristics. Maxx Ultra Cord will join Royal Biologics’ robust …

Understanding The Advantages Of Umbilical Cord Stem Cells In Regenerative Medicine | 9/15/2019

… do not develop any age-related issues. They easily maintained vital properties. A person’s body easily tolerates these because it came from them. They fully match the person’s individual characteristics. When it comes to regenerative medicine there are very few situations where no rejection occurs. This is that exception. That is one of the reasons it’s so advantageous. As well as saving your child well into the future it can …

Vitality Healthcare c/o Shull Media Partners - Ad from 2019-09-15 | Ad Vault | qctimes.com | 9/15/2019

… hrs ago Ad details HEALTHY TOMORROW Advertisement FREE EDUCATIONAL SEMINAR! SEE DETAILS BELOW FOR DATES AND TIMES NEAR YOU TIRED OF LIVING WITH THE PAIN OF NEUROPATHY? Maybe it’s time you start thinking about Regenerative Medicine Millions Suffer from Peripheral Neuropathy You don’t have to suffer from the debilitating effects of Peripheral Neuropathy anymore. We invite you to our Free Cellular Medicine Seminar to learn if it will help. This …

Vitality Healthcare c/o Shull Media Partners - Ad from 2019-09-15 | Medical Care | qctimes.com | 9/15/2019

… hrs ago Ad details HEALTHY TOMORROW Advertisement FREE EDUCATIONAL SEMINAR! SEE DETAILS BELOW FOR DATES AND TIMES NEAR YOU TIRED OF LIVING WITH THE PAIN OF NEUROPATHY? Maybe it’s time you start thinking about Regenerative Medicine Millions Suffer from Peripheral Neuropathy You don’t have to suffer from the debilitating effects of Peripheral Neuropathy anymore. We invite you to our Free Cellular Medicine Seminar to learn if it will help. This …

Medical Device Innovations Furthering FemTech, 2019 Report | PR Newswire | 9/14/2019

… driving and hinder the market growth Key Topics Covered: 1. Executive Summary 1.1 Scope of Research 1.2 Research Methodology 1.3 Summary of TechVision’s FemTech Innovation Ecosystem 1.4 The Publisher’s Perspective: FemTech is Fueled by Digital Health and Innovations Surgical Tech 2. Technology Snapshot and Trends 2.1 Emerging Demographic Trends and Effect on Women’s Health 2.2 Emerging Socio-economic Trends Impacting the Market 2.3 FemTech Innovations Cater to Both Patients (B2C …

2019 Sartorius & Science Prize for Regenerative Medicine & Cell Therapy | 9/14/2019

The Sartorius & Science Prize for Regenerative Medicine & Cell Therapy is an annual prize aimed at supporting and encouraging scientists focused on basic or translational research that advances medical progress in regenerative medicine and cell therapy. Entries can be made in the fields of regenerative medicine, cell therapy, gene therapy, immunotherapy as well as materials and tissue engineering. Established in 2017, the prize is awarded for outstanding research performed by the …

Telomere dysfunction impairs epidermal stem cell specification and differentiation by disrupting BMP/pSmad/P63 signaling | 9/14/2019

Affiliation State Key Laboratory of Medicinal Chemical Biology, Nankai University, Tianjin, China ⨯ Zhenyu Ju, Roles Resources, Affiliation Key Laboratory of Regenerative Medicine of Ministry of Education, Guangzhou Regenerative Medicine and Health Guangdong Laboratory, Institute of Aging and Regenerative Medicine, Jinan University, Guangzhou, China ⨯ Roles Methodology, Resources, Validation, E-mail: (YL); (LL) Affiliation Yale Fertility Center and Department of OB/GYN, Yale University School of Medicine, New Haven, CT, Investigation, Supervision …

Genetic Mechanisms Involved in Vision Decoded: Here’s How | 9/14/2019

Font : A- A+ Highlights: The genetic mechanisms involved in migration of neurons from the retina to the brain has been discovered This neuronal migration plays a key role in generation of vision in humans This could have important applications in regenerative medicine The complex molecular mechanism involved in the formation of the retina and differentiation of retinal and neuronal cells into the various components of the visual system in mammals …

Vitality Healthcare c/o Shull Media Partners - Ad from 2019-09-14 | Ad Vault | qctimes.com | 9/14/2019

… hrs ago Ad details HEALTHY TOMORROW Advertisement FREE EDUCATIONAL SEMINAR! SEE DETAILS BELOW FOR DATES AND TIMES NEAR YOU TIRED OF LIVING WITH THE PAIN OF NEUROPATHY? Maybe it’s time you start thinking about Regenerative Medicine Millions Suffer from Peripheral Neuropathy You don’t have to suffer from the debilitating effects of Peripheral Neuropathy anymore. We invite you to our Free Cellular Medicine Seminar to learn if it will help. This …

Drs. Jeffrey Wang, James Chappuis & more: 10 spine, neurosurgeons making the news | 9/13/2019

Here are 10 spine and neurosurgeons making headlines this week. Greenbelt, Md.-based Advanced Pain Medicine Institute Orthopaedic, Sports Health & Regenerative Medicine recently added Said Oman, MD, to its medical staff. Dr. Oman won the Kambin Foundation Annual Award for endoscopic spine surgery research and received the Lifetime-Time Achievement Award by the World Congress of Spine Endoscopy in July. President of the North American Spine Society, Jeffrey Wang, MD …

Endoscopic spine surgeon Dr. Said Osman joins Advanced Pain Medicine Institute | 9/13/2019

Greenbelt, Md.-based Advanced Pain Medicine Institute Orthopaedic, Sports Health & Regenerative Medicine recently added Said Oman, MD, to its medical staff. Four things to know: 1. Dr. Osman specializes in endoscopic and endoscopically assisted spine surgery. 2. He won the Kambin Foundation Annual Award for endoscopic spine surgery research and received the Lifetime-Time Achievement Award by the World Congress of Spine Endoscopy in July. 3. The Osman Approach, developed …

Scientists sharpen gene editing tool | Phys Org | 9/13/2019

Wake Forest Institute for Regenerative Medicine scientists have fine-tuned their delivery system to deliver a DNA editing tool to alter DNA sequences and modify gene function. The improved “hit and run” system works faster and is more efficient. “With this new method we are able to package together in one lentiviral capsid both essential components (Cas9 protein and guide RNA) for the CRISPR mediated gene editing,” said Baisong Lu …

SANUWAVE to Attend a Total of Eight Medical Conferences in the Fourth Quarter of 2019 Supported by Symposiums, Posters, and KOLs | 9/13/2019

… is a shockwave technology company initially focused on the development and commercialization of patented noninvasive, biological response activating devices for the repair and regeneration of skin, musculoskeletal tissue and vascular structures. SANUWAVE’s portfolio of regenerative medicine products and product candidates activate biologic signaling and angiogenic responses, producing new vascularization and microcirculatory improvement, which helps restore the body’s normal healing processes and regeneration. SANUWAVE applies its patented PACE® technology in wound …

Food and Drug Administration

Allergan and Molecular Partners Announce Acceptance of U.S. FDA Biologics License Application and Validation of EMA Marketing Authorisation for Abicipar pegol in Patients with Neovascular (Wet) Age-related Macular Degeneration | PR Newswire | 9/9/2019

… a clinical-stage biotechnology company developing a new class of drugs known as DARPin® platform, today announced that the U.S. Food and Drug Administration (FDA) has accepted a Biologics License Application (BLA) and the European … developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world. Allergan markets a portfolio of leading brands and best-in-class products primarily focused on four key …

Lineage Cell Therapeutics Announces Issuance of U.S. Patent for Method of Treating Spinal Cord Injury With Stem Cell-Derived Oligodendrocyte Progenitor Cells | Business & Finance | heraldchronicle.com | Business Wire | 9/4/2019

Regenerative Medicine . OPC1 has received Regenerative Medicine Advanced Therapy (RMAT) designation for the treatment of acute SCI and has been granted Orphan Drug designation from the U.S. Food and Drug Administration (FDA). About Lineage Cell Therapeutics, Inc. Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its proprietary cell-based therapy platform and associated development and manufacturing …

Biotech

When Will Avita Medical Limited (ASX:AVH) Turn A Profit? | Yahoo News | 9/12/2019

… ASX:AVH) Turn A Profit? Simply Wall St Reblog Avita Medical Limited’s ( ASX:AVH ) : Avita Medical Limited operates as a regenerative medicine company in the Asia Pacific, Europe, the Middle East, Africa, and the Americas … our latest analysis for Avita Medical Consensus from the 2 Biotechs analysts is AVH is on the verge of breakeven. They anticipate the company to incur a final loss in 2021, before generating positive profits …

AIVITA Biomedical Launches Professional ROOT of SKIN™ MD Skincare Line in Japan | PR Newswire | 9/10/2019

IRVINE, Calif. , Sept. 10, AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications, announced today the launch of the Company’s professional ROOT of SKIN™ MD brand of rejuvenating skincare products in Japan … advancement of commercial and clinical-stage programs utilizing curative and regenerative medicines. Founded in 2016 by pioneers in the stem cell industry, AIVITA Biomedical utilizes its expertise in stem cell growth and directed, high-purity

National Institutes of Health

FDA Provides Guidance on Clinical Pathway to Marketing Application for Revascor in End-Stage Heart Failure Patients With an LVAD | Markets Insider | Business Insider | 8/27/2019

… of an LVAD implant in end-stage heart failure patients.” Revascor is being developed for these patients under existing FDA Regenerative Medicine Advanced Therapy (RMAT) and Orphan Drug Designations. About Orphan Drug Designation The FDA’s … heart failure patients with LVADs, conducted by the United States National Institutes of Health (NIH), a single intra-myocardial dose of Revascor resulted in a 70% reduction in GI bleeding and associated hospitalizations. The results …

Clinical Data

Vineti and Cryoport Collaborate to Bring Integrated Solutions to the Global Regenerative Therapy Market | Globe Newswire | 9/4/2019

… growing market. We are working constantly to secure valuable collaborations that expand our ecosystem of temperature-controlled solutions for the regenerative medicine market. As the regenerative medicine market matures, the demands of cell and gene … a digital platform of record to integrate logistics, manufacturing and clinical data for personalized therapies. The Vineti platform supports the full continuum of patient-specific therapies, including cancer vaccines and autologous and allogeneic therapies. The …

FDA Provides Guidance on Clinical Pathway to Marketing Application for Revascor in End-Stage Heart Failure Patients With an LVAD | Markets Insider | Business Insider | 8/27/2019

… that Revascor reduced major mucosal bleeding events can support product marketing authorization through a Biologics License Application (BLA), with confirmatory clinical data. FDA agreed on a confirmatory Phase 3 trial of Revascor in LVAD patients … Revascor is being developed for these patients under existing FDA Regenerative Medicine Advanced Therapy (RMAT) and Orphan Drug Designations. About Orphan Drug Designation The FDA’s Orphan Drug Designation Program provides orphan status to drugs and …

AMA

Generex Announces Acquisition of Additional 38% of Subsidiary Olaregen Therapeutix in an Up-Market Transaction with a Share Exchange of GNBT Stock at $2.50 | Globe Newswire | 8/19/2019

… debt NuGenerex Immuno-Oncology Spin-out Evaluating Acquisition of a Hospital Network Completed Audit of Direct-to-Patient Pharmacy Business MIRAMAR, Fla., Generex Biotechnology Corporation ( www.generex.com ) (OTCQB:GNBT) (“Generex”) is pleased to announce that Generex … call center. About Olaregen Therapeutix Olaregen Therapeutix, Inc. is a regenerative medicine company focused on the development, manufacturing and commercialization of products that fill unmet needs in the current wound care market. Generex aims to …

Generex Announces Acquisition of Additional 38% of Subsidiary Olaregen Therapeutix in an Up-Market Transaction with a Share Exchange of GNBT Stock at $2.50 | Markets Insider | Business Insider | 8/19/2019

… debt NuGenerex Immuno-Oncology Spin-out Evaluating Acquisition of a Hospital Network Completed Audit of Direct-to-Patient Pharmacy Business MIRAMAR, Fla., Aug. 19, 2019 (GLOBE NEWSWIRE) – Generex Biotechnology Corporation ( www.generex.com ) (OTCQB:GNBT) (“Generex”) is … call center. About Olaregen Therapeutix Olaregen Therapeutix, Inc. is a regenerative medicine company focused on the development, manufacturing and commercialization of products that fill unmet needs in the current wound care market. Generex aims to …

NIH

Steadman Philippon Research Institute’s Vail Scientific Summit to Celebrate Its Fifth Year | Globe Newswire | 8/19/2019

… Research Institute’s Vail Scientific Summit to Celebrate Its Fifth Year Canon Medical to serve as first title sponsor; “Advances in Regenerative Medicine” is 2019 theme August 19, 2019 14:43 ET Source: The Steadman Clinic and … we will have representatives from the National Institutes of Health (NIH), Orthopaedic Resarch Society (ORS), Naval Medical Research Center, as well as speakers discussing relevant Food and Drug Administration (FDA) regulations. The enormous and enduring …

AgeX Therapeutics, Inc. Reports Second Quarter 2019 Financial Results and Provides Business Update | Business & Finance | heraldchronicle.com | Business Wire | 8/14/2019

… investor conferences during the quarter. These included a presentation by Dr. West at Undoing Aging in Berlin, Germany, on AgeX’s regenerative medicine product development. At the conference, Dr. West also presented data relating to the … 47,000 of allowable expenses under its research grant from the NIH. AgeX had no grant revenues in the same period in 2018. Operating expenses : Operating expenses for the three months ended June 30, 2019 were …

ACA

James T. Willerson, MD is recognized by Continental Who’s Who | PR Newswire | 8/23/2019

… institution, Texas Heart Institute is recognized internationally for research programs in cardiology, cardiovascular surgery, stem cell and gene therapy, and regenerative medicine. Continue Reading (PRNewsfoto/Continental Who’s Who) A respected writer in the medical field … his education and training, Dr. Willerson graduated from San Antonio Academy, San Antonio, Texas in 1953 and from the Texas Military Institute (TMI), San Antonio, Texas in 1957. Following this, Dr. Willerson received his Bachelor …

James T. Willerson, MD is recognized by Continental Who’s Who | Markets Insider | Business Insider | 8/23/2019

… institution, Texas Heart Institute is recognized internationally for research programs in cardiology, cardiovascular surgery, stem cell and gene therapy, and regenerative medicine. A respected writer in the medical field, Dr. Willerson published many papers including … his education and training, Dr. Willerson graduated from San Antonio Academy, San Antonio, Texas in 1953 and from the Texas Military Institute (TMI), San Antonio, Texas in 1957. Following this, Dr. Willerson received his Bachelor …

Medical Research

Global Regenerative Medicine Market by Type, Application, Region & Country (2019 Edition): Opportunities & Forecasts (2014-2024) | Financial Buzz | 9/9/2019

Dublin, The “Global Regenerative Medicine Market: Analysis By Type (Cell Therapy, Tissue Engineered, Gene Therapy), By Application, By Region, By Country (2019 Edition): Opportunities and Forecast (2014-2024)” report has been added to ResearchAndMarkets.com’s offering. The … rise in the prevalence of chronic diseases and increase in medical research investments, the global market for regenerative medicine has been advancing at an augmented pace. The growth has been primarily driven by the search

Global Ophthalmics Partnering Deals Directory 2019: Headline Value, Upfront Payment, Milestone Payments and Royalty Rates Since 2014 | PR Newswire | 9/6/2019

… Foundation Bright Optical Brill Pharma Broda Technologies Buck Institute for Age Research C-Bridge Capital Caladrius Biosciences California Institute for Regenerative Medicine California Stem Cell Cambridge Research Biochemicals Cannabics Pharmaceuticals Cardinal Health Carl Zeiss Meditec … McKesson McMaster University MD Distributor MEAgate International Mectizan Donation Program Medical Research Foundation Mediconsult.com MedImmune Medio-Haus MeiraGTx Memira Holding Merck and Co Merck Animal Health Merge Healthcare Merz Meyer Children’s Hospital of Florence MicroConstants …

Cures Act

FDA Provides Guidance on Clinical Pathway to Marketing Application for Revascor in End-Stage Heart Failure Patients With an LVAD | Markets Insider | Business Insider | 8/27/2019

… of an LVAD implant in end-stage heart failure patients.” Revascor is being developed for these patients under existing FDA Regenerative Medicine Advanced Therapy (RMAT) and Orphan Drug Designations. About Orphan Drug Designation The FDA’s … Designation The FDA’s RMAT designation program under the 21st Century Cures Act aims to expedite the development of regenerative medicine therapies intended for the treatment of serious diseases and life-threatening conditions. RMAT designation allows …

21st Century Cures Act

FDA Provides Guidance on Clinical Pathway to Marketing Application for Revascor in End-Stage Heart Failure Patients With an LVAD | Markets Insider | Business Insider | 8/27/2019

… of an LVAD implant in end-stage heart failure patients.” Revascor is being developed for these patients under existing FDA Regenerative Medicine Advanced Therapy (RMAT) and Orphan Drug Designations. About Orphan Drug Designation The FDA’s … About RMAT Designation The FDA’s RMAT designation program under the 21st Century Cures Act aims to expedite the development of regenerative medicine therapies intended for the treatment of serious diseases and life-threatening conditions. RMAT …

Allergan

Allergan Shareholder Meetings Scheduled for October 14, 2019 | PR Newswire | 9/11/2019

… FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION Allergan plc (NYSE: AGN ) announced that following a hearing today before the Irish High Court … developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world. Allergan markets a portfolio of leading brands and best-in-class products primarily focused on four key …

Allergan and Molecular Partners Announce Acceptance of U.S. FDA Biologics License Application and Validation of EMA Marketing Authorisation for Abicipar pegol in Patients with Neovascular (Wet) Age-related Macular Degeneration | PR Newswire | 9/9/2019

DUBLIN Allergan plc (NYSE: AGN ), a leading global pharmaceutical company with a heritage of more than 70 years in eye care, and Molecular Partners (SIX: MOLN), a clinical-stage biotechnology company developing a new class … developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world. Allergan markets a portfolio of leading brands and best-in-class products primarily focused on four key

MiMedx

Amniotic Membrane Market to Register an Exponential CAGR of 12.16% to cross USD 1,210.9 million by 2023 – Market Research Future | Globe Newswire | 6/20/2019

… Membrane Market Research Report Insights and Industry Analysis by Type (Cryopreserved and Lyophilized), Application (Surgical Wounds, Ophthalmology, Stem Cell Biology, Regenerative Medicine), End User (Hospitals & Clinics), & Region, Competitive Market Size, Share, Trends, and Forecast, 2018-2023 … Inc. (US), Skye Biologics Inc. (California), Amniox Medical, Inc. (Florida), MiMedx (US), Katena Products, Inc. (US), Amnio Technology, LLC (US), Human Regenerative Technologies, LLC (US), and Osiris Therapeutics, Inc. (US). Market Segmentation: This MRFR report …

Bone Therapeutics announces results of Annual General Meeting | Globe Newswire | 6/12/2019

… regenerative medicine. She has a strong track record of supporting life sciences companies to grow and evolve from start-up stage to fully integrated biopharma companies and has built an impressive business and medical network over the years. She was Senior Vice President of MiMedx, a biopharma company focused on the development and commercialisation of regenerative and therapeutic biologicals in wound care, and spine and sports medicine. Prior to that …

Novartis

Regenerative Medicine Market to Reach US$ 151,949.5 Mn by 2026; Novartis’ EU Approval to Favor Market Growth, Says Fortune Business Insights | Benzinga | 8/26/2019

PUNE, India , Aug. 26, 2019 /PRNewswire/ – The global Regenerative Medicine Market is likely to expand considerably in the coming years due to growing applications in the treatment of chronic diseases. According to a report published … favor the growth of the market in the forthcoming years. Novartis Receives EU Approval for Luxturna The severity of chronic diseases has led to the demand for efficient medicines. The ability of regenerative medicine to

Regenerative Medicine Market to Reach US$ 151,949.5 Mn by 2026; Novartis’ EU Approval to Favor Market Growth, Says Fortune Business Insights | Markets Insider | Business Insider | 8/26/2019

PUNE, India , Aug. 26, 2019 /PRNewswire/ – The global Regenerative Medicine Market is likely to expand considerably in the coming years due to growing applications in the treatment of chronic diseases. According to a report published … favor the growth of the market in the forthcoming years. Novartis Receives EU Approval for Luxturna The severity of chronic diseases has led to the demand for efficient medicines. The ability of regenerative medicine to

BioLife

BioLife Solutions Strengthens Sales Team with Key Leadership Additions | PR Newswire | 8/28/2019

BOTHELL, Wash. , Aug. 28, BioLife Solutions , Inc. (NASDAQ: BLFS ), a leading developer and supplier of a portfolio of best-in-class bioproduction tools for cell and gene therapies, today announced the hiring of two key … HypoThermosol ® shipping and storage media are highly valued in the regenerative medicine, biobanking and drug discovery markets. These biopreservation media products are serum-free and protein-free, fully defined, and are formulated to reduce preservation

BioLife Solutions Announces Second Quarter 2019 Financial Results | PR Newswire | 8/9/2019

BOTHELL, Wash. BioLife Solutions , Inc. (NASDAQ: BLFS ) (“BioLife” or the “Company”), a leading developer and supplier of a portfolio of best-in-class bioproduction tools for cell and gene therapies, today reported financial results and … of which were cell and gene therapy companies in the regenerative medicine market segment. Received 14 new cross-reference requests for our FDA master files for CryoStor and HypoThermosol. Worldwide Distributor Network Product revenue: $2.2

iMedX

Amniotic Membrane Market to Register an Exponential CAGR of 12.16% to cross USD 1,210.9 million by 2023 – Market Research Future | Globe Newswire | 6/20/2019

… Membrane Market Research Report Insights and Industry Analysis by Type (Cryopreserved and Lyophilized), Application (Surgical Wounds, Ophthalmology, Stem Cell Biology, Regenerative Medicine), End User (Hospitals & Clinics), & Region, Competitive Market Size, Share, Trends, and Forecast, 2018-2023 … Inc. (US), Skye Biologics Inc. (California), Amniox Medical, Inc. (Florida), MiMedx (US), Katena Products, Inc. (US), Amnio Technology, LLC (US), Human Regenerative Technologies, LLC (US), and Osiris Therapeutics, Inc. (US). Market Segmentation: This MRFR report …

Global Regenerative Medicine Market to 2024 - Dominated by Kite Pharma, Novartis, Vericel Corp, Integra LifeSciences, Wright Medical, MiMedx, Osiris Therapeutics, Stryker Corp, and Spark Therapeutics - ResearchAndMarkets.com | Business Wire | 4/18/2019

DUBLIN- The “Regenerative Medicine Market by Type [Cell-Based Immunotherapy & Cell Therapy (Allogeneic & Autologous Products), Tissue Engineering, Gene Therapy], Applications (Wounds & Dermal, Musculoskeletal, Oncology), Region - Global Forecast to 2024” report has been added to ResearchAndMarkets.com’s … Switzerland), Vericel Corporation (US), Integra LifeSciences (US), Wright Medical (US), MiMedx (US), Osiris Therapeutics (US), Stryker Corporation (US), and Spark Therapeutics (US). Product launches and acquisitions are the key growth strategies followed by most players

Thermo Fisher

BioLife Solutions Announces Second Quarter 2019 Financial Results | PR Newswire | 8/9/2019

… regenerative medicine market segment. Received 14 new cross-reference requests for our FDA master files for CryoStor and HypoThermosol. Worldwide Distributor Network Product revenue: $2.2 million ; representing 33% of total revenue with 31% growth over the same period last year. Key worldwide distributors include: STEMCELL Technologies, MilliporeSigma, Thermo Fisher and VWR. Second Quarter and Six Month 2019 Financial Results BioLife Solutions is presenting various financial metrics under U.S. Generally Accepted …

BioLife Solutions Announces Second Quarter 2019 Financial Results - NASDAQ.com | 8/9/2019

… regenerative medicine market segment. Received 14 new cross-reference requests for our FDA master files for CryoStor and HypoThermosol. Worldwide Distributor Network Product revenue: $2.2 million; representing 33% of total revenue with 31% growth over the same period last year. Key worldwide distributors include: STEMCELL Technologies, MilliporeSigma, Thermo Fisher and VWR. Second Quarter and Six Month 2019 Financial Results BioLife Solutions is presenting various financial metrics under U.S. Generally Accepted …

Pfizer

Visiongain Report Analyses Leading Players within the $1.4bn Pharmaceutical Wholesale & Distribution Market | PR Newswire | 9/6/2019

… OCP Ohki Health Care Holdings, Inc. Oncology Therapeutics Oncoprod OptumRx P.J.D. Network PALTAC CORPORATION Paltac Corporation Panpharma Pfercos Co., Ltd. Pfizer PharMEDium Polska Grupa Farmaceutyczna Prodigy Health Profarma Distribuidora de Produtos Farmaceuticos SA Prosper Protek … Top 20 Global Respiratory Inhalers Manufacturers 2019 Top 25 Translational Regenerative Medicine Manufacturers 2019 Pharma Leader Series: Top Generic Drug Producers Market Forecast 2019-2029 SOURCE Visiongain …

‘It’s a little ‘Star Trekky’’: How this S.F. startup looks to create 3D-printed organs | The Business Journals | 8/23/2019

… the use of that technology to actually create tissue and organs for research and transplantation. Is it biotech? Hard tech? Regenerative medicine? “We’re at the nexus of a few different technologies,” said Matheu, the company’s … Matheu, Prellis cofounder Noelle Mullin (now a senior scientist at Pfizer Inc.) and colleagues took the laser system, read up on it and merged techniques of tissue engineering with laser-based printing from a computer …

Merck

Merck KGaA, Darmstadt, Germany, Announces FDA Breakthrough Therapy Designation for Investigational Therapy Tepotinib in Patients with Metastatic NSCLC with METex14 Skipping Alterations | PR Newswire | 9/11/2019

Not intended for UK-based media DARMSTADT, Germany , Sept. 11, 2019 /PRNewswire/– Merck KGaA, Darmstadt, Germany , a leading science and technology company, which operates its biopharmaceutical business as EMD Serono in the US and Canada … early practical application for innovative pharmaceutical products, medical devices and regenerative medicines. Tepotinib is also being investigated in the INSIGHT 2 study (NCT03940703) in combination with the tyrosine kinase inhibitor (TKI) osimertinib in epidermal growth

AMNICELL Appoints Helen Ljungdahl Round as CEO | Business & Finance | heraldchronicle.com | Business Wire | 8/26/2019

… President of Global Marketing & Business Development for GN Hearing, and, before that, numerous executive leadership positions of increasing responsibility at Merck & Co, Inc, working in EU, Middle East/Africa, North America, Latin America and Asia … well as delivering strong business results. ” Helen Ljungdahl Round said: “Regenerative medicine holds a lot of future potential, and AMNICELL is uniquely positioned with its advanced technology using amniotic fluid and pluripotent stem cells to …

Medtronic

Visiongain Report Analyses Leading Players within the $1.4bn Pharmaceutical Wholesale & Distribution Market | PR Newswire | 9/6/2019

… Springfield Medical Specialties Distributors MEDICEO CORPORATION Medicine Shoppe Canada Inc. MEDIE Co., Ltd. MEDIPAL HOLDINGS CORPORATION Mediq Apotheken Nederland B.V. Medtronic Meinan Distribution Center Metro Medical Supply Inc Mitsubishi MM CORPORATION Morris & Dickson Co. LLC … Top 20 Global Respiratory Inhalers Manufacturers 2019 Top 25 Translational Regenerative Medicine Manufacturers 2019 Pharma Leader Series: Top Generic Drug Producers Market Forecast 2019-2029 SOURCE Visiongain …

Regenerative Medicine Market to Reach US$ 151,949.5 Mn by 2026; Novartis’ EU Approval to Favor Market Growth, Says Fortune Business Insights | Markets Insider | Business Insider | 8/26/2019

PUNE, India , Aug. 26, 2019 /PRNewswire/ – The global Regenerative Medicine Market is likely to expand considerably in the coming years due to growing applications in the treatment of chronic diseases. According to a report published … operating in the market are Integra LifeSciences Corporation, CELGENE CORPORATION, Medtronic, American CryoStem Corporation, Tissue Regenix, Avita Medical, Osiris Therapeutics, Inc., Wright Medical Group N.V., Smith & Nephew, and Integra LifeSciences Corporation. Table of Content: Introduction

Athersys

Global Translational Regenerative Medicines Market by Product Type, Therapy, Application and Geography - Forecast to 2026 - ResearchAndMarkets.com | Business Wire | 7/26/2019

DUBLIN- The “Translational Regenerative Medicines - Global Market Outlook (2017-2026)” report has been added to ResearchAndMarkets.com’s offering. According to this research, the Global Translational Regenerative Medicines Market is growing at a CAGR of 13.9% from 2017 … Translational Regenerative Medicines Market include Vericel Corporation, Gamida Cell Ltd., Athersys, Inc., Orthofix International N.V, Anika Therapeutics, Novartis, Celgene Corporation, Brainstorm Cell Therapeutics Inc., Nuvasive, Inc., and Medipost. What the report offers: Market share assessments

The Alliance for Regenerative Medicine Releases List of Presenting Companies at the 2019 Cell & Gene Meeting on the Mesa | Globe Newswire | 7/24/2019

July 24, 2019 10:30 ET Source: Alliance for Regenerative Medicine WASHINGTON, D.C., via NEWMEDIAWIRE – The Alliance for Regenerative Medicine (ARM), the international advocacy organization for the cell and gene therapy and broader regenerative medicine sector … Biomedical, Amicus Therapeutics, Astellas Institute for Regenerative Medicine, Atara Biotherapeutics, Athersys, Autolus, Avectas, AVROBIO, Axovant Gene Therapies, BioLife Solutions, BioTime, bluebird bio, BlueRock Therapeutics, Caladrius Biosciences, Caribou Biosciences, CARISMA Therapeutics, Casebia Therapeutics, CCRM, Cellect Biotechnology

Versant Ventures

Kirk Falconer wrote a new post, Bayer to acquire VC-backed BlueRock Therapeutics in $1.3 bln deal, on the site PE Hub | 8/8/2019

… held by Bayer, a German healthcare and nutrition business. In 2016, Bayer partnered with U.S. life sciences venture capital firm Versant Ventures in founding BlueRock with a US$225 million financing . Bayer said it will … leading engineered cell therapy company with a mission to develop regenerative medicines for intractable diseases. BlueRock Therapeutics’ CELL+GENE™ platform harnesses the power of cells for new medicines across neurology, cardiology and immunology indications. BlueRock …

Bayer AG buys BlueRock Therapeutics for $1 bln | PE Hub | 8/8/2019

Bayer AG buys BlueRock Therapeutics for $1 bln August 8, 2019 Bayer AG has acquired BlueRock Therapeutics from Versant Ventures for up to $1 billion. BlueRock, a biotech, focuses on stem cell research. PRESS RELEASE … leadership and operations across Canada and the U.S.” “Prioritization of regenerative medicine as a new frontier for investment allowed us to develop a position in a new field with two to three years of lead

Amgen Ventures

Term Sheet – Thursday, November 9 | Fortune | 11/9/2017

… regenerative medicine company, raised $25 million in Series B funding. Investors include Amgen Ventures. • Oyster Point Pharmaceuticals Inc. , a San Francisco-based developer of treatments for dry eye and other diseases of the ocular surface, raised $22 million in Series A funding. New Enterprise Associates and Versant Ventures led the round. • Broker Genius , a New York-based dynamic pricing technology for the secondary ticket market, raised $15 million in Series …

Fortuna Fix Announces Series B Financing, Adding Amgen Ventures and Macnguyen Family Office as Shareholders | PR Newswire | 11/8/2017

Fortuna Fix Announces Series B Financing, Adding Amgen Ventures and Macnguyen Family Office as Shareholders News provided by Nov 08, 2017, 07:00 ET Share this article LONDON and MONTREAL , Nov. 8, 2017 /PRNewswire/ – Fortuna Fix (“ Fortuna “), a private, clinical-stage Regenerative Medicine company is aiming to be the first to bring to the clinic a patient’s own neural stem cells (autologous) produced by direct reprogramming (“drNPCs”) to replace lost neuronal …

Jefferies Financial Group

Pacira Biosciences, Inc. (PCRX) CEO David Stack on Q1 2019 Results - Earnings Call Transcript | Seeking Alpha | 5/3/2019

Pacira Biosciences, Inc. (NASDAQ: PCRX ) Q1 2019 Earnings Conference Call May 2, 2019 8:30 AM ET Company Participants Susan Mesco - Head, IR David Stack - Chairman & CEO Richard Scranton - Chief Medical Officer Charles Reinhart - CFO Conference Call Participants David Amsellem - Piper Jaffray Companies Randall Stanicky - RBC Capital Markets David Steinberg - Jefferies Vasiliana Moussatos - Wedbush Securities Gary Nachman - BMO Capital Markets Serge Belanger - Needham & Company Operator Good morning, ladies and gentlemen, and …

Biogen Inc. (BIIB) CEO Michel Vounatsos on Q1 2019 Results - Earnings Call Transcript | Seeking Alpha | 4/25/2019

Biogen Inc. (NASDAQ: BIIB ) Q1 2019 Results Earnings Conference Call April 24, 2019 8:00 AM ET Company Participants Matt Calistri - Vice President, Investor Relations Michel Vounatsos - Chief Executive Officer Michael Ehlers - Executive Vice President of Research & Development Jeff Capello - Chief Financial Officer Conference Call Participants Ying Huang - Bank of America. Merrill Lynch Robyn Karnauskas - Citigroup Geoff Meacham - Barclays Michael Yee - Jefferies Cory Kasimov - JPMorgan Umer Raffat - Evercore Alethia Young - Cantor …

Maxim Group

Dawson James Securities Appoints Jason Kolbert to Director of Research | Globe Newswire | 6/10/2019

… regenerative medicine (stem cells). Prior to joining Dawson James, Mr. Kolbert spent the prior year as a senior biotechnology analyst at HC Wainwright and spent the previous seven years at the Maxim group, where he was an Executive Managing Director and the Head of Healthcare Research at the firm. During this period Jason and his team covered 80 names across the healthcare vertical. Jason’s Wall Street career began with seven …

Mesoblast’s (MESO) CEO Silviu Itescu on Q3 2019 Results - Earnings Call Transcript | Seeking Alpha | 5/31/2019

… Officer Josh Muntner – Chief Financial Officer Joanne Kurtzberg – Distinguished Professor of Pediatrics Conference Call Participants Mark Breidenbach – Oppenheimer Jason McCarthy – Maxim Group Jeffrey Cohen – Ladenburg Thalmann Operator Hello, and welcome to Mesoblast’s Financial Update and … Acute Graft Versus Host disease. This was the first allergenic regenerative medicine product approved in Japan. Through a license arrangement with Takeda, Alofisel approved for perianal fistulae was the first allergenic regenerative medicine product approved …

Atlas Venture

New Data Published in Journal Cell Show Robust Mobilization of Highly Engraftable Stem Cells in Mouse Models with Combination of GROβ and Plerixafor | Business Wire | 12/8/2017

… Department of Stem Cell and Regenerative Biology, co-director of Harvard Stem Cell Institute, and Director of the Center for Regenerative Medicine at MGH. Dr. Scadden is also a scientific co-founder of Magenta. “Magenta’s … Therapeutics was launched in 2016 by Third Rock Ventures and Atlas Venture and is headquartered in Cambridge, Mass. For more information, please visit www.magentatx.com . Contacts Magenta Therapeutics: Manisha Pai, 857-242-1155 Vice President, Communications & Investor Relations …

Third Rock Ventures

New Data Published in Journal Cell Show Robust Mobilization of Highly Engraftable Stem Cells in Mouse Models with Combination of GROβ and Plerixafor | Business Wire | 12/8/2017

… Department of Stem Cell and Regenerative Biology, co-director of Harvard Stem Cell Institute, and Director of the Center for Regenerative Medicine at MGH. Dr. Scadden is also a scientific co-founder of Magenta. “Magenta’s … marrow transplant medicine, Magenta Therapeutics was launched in 2016 by Third Rock Ventures and Atlas Venture and is headquartered in Cambridge, Mass. For more information, please visit www.magentatx.com . Contacts Magenta Therapeutics: Manisha Pai, 857-242-1155 Vice …

RBC Capital Markets

Pacira Biosciences, Inc. (PCRX) CEO David Stack on Q1 2019 Results - Earnings Call Transcript | Seeking Alpha | 5/3/2019

… Chairman & CEO Richard Scranton - Chief Medical Officer Charles Reinhart - CFO Conference Call Participants David Amsellem - Piper Jaffray Companies Randall Stanicky - RBC Capital Markets David Steinberg - Jefferies Vasiliana Moussatos - Wedbush Securities Gary Nachman - BMO Capital Markets … 1.5 years. The strategy is that when you look at regenerative medicine and especially in the orthopedics field, a lot of that is being practiced by the docs where we already have a relationship. So …

AVITA Medical to Present at RBC Capital Markets 2019 Healthcare Conference | Business Wire | 5/2/2019

VALENCIA, Calif. & MELBOURNE, Australia–( BUSINESS WIRE )–AVITA Medical (ASX: AVH, OTCQX: AVMXY), a global regenerative medicine company, announced that management will present at the RBC Capital Markets 2019 Healthcare Conference in New York. The presentation is being made on 21 May 2019 from 9:00 a.m. to 9:25 a.m. EDT at the InterContinental New York Barclay hotel. A copy of the slide presentation will be posted to the ASX website ( https …

First Analysis

Anika Therapeutics’ (ANIK) CEO Joseph Darling on Q1 2019 Results - Earnings Call Transcript | Seeking Alpha | 5/3/2019

… Cheung – Chief Financial Officer Joseph Darling – President and Chief Executive Officer Conference Call Participants Mike Petusky – Barrington Research Joe Munda – First Analysis Jim Sidoti – Sidoti & Company Operator Good evening, ladies and gentlemen, and welcome to … of innovative product launches across the continuum of orthopedic and regenerative medicine therapies. We achieved double digit revenue growth year-over-year in all product lines, including in both our U.S. and international viscosupplement businesses …

Anika Therapeutics Inc (ANIK) Q1 2019 Earnings Call Transcript - Nasdaq.com | 5/2/2019

… Company positioned to deliver on a consistent and successful series of innovative product launches across the continuum of orthopedic and regenerative medicine therapies. We achieved double-digit revenue growth year-over-year in all product … next question comes from the line of Joe Munda with First Analysis. Your line is now open. Joseph P. Munda – First Analysis Securities Corporation – Analyst Good evening, Joe and Sylvia. Can you hear me OK …

MPM Capital

AlloVir Announces Viralym-M Granted Regenerative Medicine Advanced Therapy (RMAT) Designation for the Treatment of Hemorrhagic Cystitis Caused by BK Virus in Adults and Children Following Allogeneic HSCT | Business Wire | 6/11/2019

Classifieds AP AlloVir Announces Viralym-M Granted Regenerative Medicine Advanced Therapy (RMAT) Designation for the Treatment of Hemorrhagic Cystitis Caused by BK Virus in Adults and Children Following Allogeneic HSCT 1 hr ago Save HOUSTON … investors are the UBS Oncology Impact Fund (OIF) managed by MPM Capital, as well as F2 Ventures. Investors also include EcoR1 Capital, Redmile Group, and Samsara BioCapital. For more information, please visit https://www.elevate.bio . View

Cell Encapsulation Markets 2019-2023: Current Market Landscape and the Future Potential of Encapsulated Cell Therapies and Affiliated Technologies | PR Newswire | 5/29/2019

… Bio ADIRA Aduro Biotech Advent Bioservices Agency for Science, Technology and Research AgenTus Therapeutics Aldagen Allele Biotechnology & Pharmaceuticals Alliance for Regenerative Medicine Allife Medical Science and Technology Allogene Therapeutics Alsace BioValley Altor BioScience ALTuCELL AlzeCure … Miltenyi Biotec Minovia Therapeutics Moderna Therapeutics MolecuVax MolMed Moraga Biotechnology MPM Capital Multimmune Mustang Bio Nantes-Atlantic National College of Veterinary Medicine, Food Science and Engineering NantKwest National Cancer Institute National Center for Advancing Translational …

SVB Leerink

AbbVie to Acquire Allergan in Transformative Move for Both Companies | PR Newswire | 6/25/2019

… in Dublin, Ireland , is a global pharmaceutical leader focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world. Allergan markets a portfolio of brands and … relation to AbbVie and Humira revenues: Societe Generale, Atlantic Equities, SVB Leerink, Piper Jaffray , Wolfe Research, Morgan Stanley, BMO, Cowen and Credit Suisse; and (ii) in relation to Allergan: JP Morgan, Credit Suisse, Guggenheim, RBC …

Cryoport Announces Proposed Public Offering of Common Stock | PR Newswire | 6/20/2019

… capital, inventory development, global infrastructure buildout and facilities expansion, sales and marketing and, potentially, acquisitions with strategic impact. Jefferies and SVB Leerink are acting as joint book-running managers for the offering. The public offering … biopharmaceutical market with logistics solutions for biologic materials, such as regenerative medicine, including immunotherapies, stem cells and CAR T-cells. Cryoport’s solutions are used by points-of-care, CRO’s, central laboratories, pharmaceutical companies, manufacturers, university …

HCA

Healthcare “futurists” to meet in Detroit on Oct. 7 | Modern Healthcare | 8/26/2019

… Regenerative medicine pioneer Tony Atala described his work in regenerating organs and tissues. And former U.S.. Surgeon General Antonia Novello provided a health policy perspective on the impact on innovation, as reported by Crain’s Detroit Business, Modern Healthcare’s sister publication . The invitation-only conference is still taking applications for attendance. Contact Ellis at sponsor Detroit International Research and Education Foundation. The meeting agenda can be found here. For HealthQuake 2019 …

Cognate BioServices Secures Growth Capital Investment from EW Healthcare to Continue to Expand Commercial Manufacturing Capacity and Services for the Cellular Therapies Industry | PR Newswire | 8/26/2019

… to support its short-term and long-term growth as it closed on a round of growth capital from EW Healthcare Partners (“EW Healthcare”). (PRNewsfoto/Cognate BioServices) “We have known Cognate and followed its progress … focused on providing the broadest range of commercialization services to regenerative medicine, cellular immunotherapy and advance cell therapy companies. Cognate provides a unique combination of custom services to companies across all points of clinical and …

Mayo Clinic

Vineti and Cryoport Collaborate to Bring Integrated Solutions to the Global Regenerative Therapy Market | Globe Newswire | 9/4/2019

Mayo Clinic, underscores Cryoport’s expanding reach within this rapidly growing market. We are working constantly to secure valuable collaborations that expand our ecosystem of temperature-controlled solutions for the regenerative medicine market. As the regenerative medicine market matures, the demands of cell and gene therapy developers are becoming increasingly complex and we are committed to enhancing our offerings with collaborations such as this one with Vineti, the industry-leading supply …

Amgen And Allergan Announce Positive Top-Line Results From Comparative Clinical Study Of ABP 798, Biosimilar Candidate To Rituxan® (Rituximab) | PR Newswire | 8/22/2019

… in Dublin, Ireland , is a global pharmaceutical leader focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world. Allergan markets a portfolio of leading brands … lymphoma/patient/adult-nhl-treatment-pdq . Accessed July 17, 2019 Mayo Clinic. Non-Hodgkin’s Lymphoma. https://www.mayoclinic.org/diseases-conditions/non-hodgkins-lymphoma/symptoms-causes/syc-20375680 . Accessed July 17, 2019 . American Cancer Society. Key Statistics …

Massachusetts General Hospital

Century Therapeutics launches with USD 250M financing for induced pluripotent stem cell (iPSC) allogeneic cell therapy platform | PR Newswire | 7/1/2019

… and the creation of new technologies, products and services. We are confident that FCDI’s cutting edge iPSC technologies and promising regenerative medicine solutions currently under development, can create new value to fulfill unmet medical needs … School and director of the Cellular Immunotherapy Cancer Center at Massachusetts General Hospital, and Hiro Nakauchi , MD, Ph.D., professor of genetics at Stanford University School of Medicine. About Century Therapeutics Century Therapeutics is harnessing the …

Follica Announces Progression to Pivotal Study Following Positive Interim Data in Male Androgenetic Alopecia | Business Wire | 6/13/2019

… for creating new hair,” said R. Rox Anderson, MD, PhD, professor of dermatology at Harvard Medical School, director of the Massachusetts General Hospital Laser Center, and scientific advisor to Follica, who conceived and developed many … group of world-renowned experts in hair follicle biology and regenerative medicine, Follica’s device platform has been shown to stimulate the development of new hair follicles and hair in three previously conducted clinical studies. The …

Harvard Medical School

‘Extraordinary’ Breakthroughs In Anti-Aging Research ‘Will Happen Faster Than People Think’ | Forbes | 8/26/2019

… research and development programs,” Market Watch reported. Investors are also closely watching Rejuvenate Bio—the start-up, co-founded by Harvard Medical School professor George Church, Market Watch reports. The company is testing 60 different … of Health (NIH) and conducted at UPIT’s McGowan Institute for Regenerative Medicine . Michael Hufford, PhD, Chief Executive Officer of LyGenesis, said the technology could address the problem of the imbalance between organ supply and demand …

Frequency Therapeutics Expands Leadership Team | Business Wire | 8/22/2019

… Executive Vice President of Clinical and Translational Science, supporting development of the company’s PCA platform, bridging the company’s research in regenerative medicine to translational and clinical science, and building corporate initiatives in medical affairs and … of Medicine in Boston and trained in Internal Medicine at Harvard Medical School and Neurology at the Johns Hopkins Hospital. William Chin, M.D., Executive Vice President, Clinical and Translational Science Dr. Chin has moved into …

Cleveland Clinic

Visiongain Report Analyses Leading Players Within the Translational Regenerative Medicine Manufacturers Market | Markets Insider | Business Insider | 5/23/2019

LONDON , May 23, 2019 /PRNewswire/ – In 2018, the global translational regenerative medicine is estimated at $28bn . The global translational regenerative medicine market is highly competitive and fragmented with the presence of several vendors. The competition … Xcellerex List of Organizations Mentioned in the Report Brown University Cleveland Clinic European Commission European Medicines Agency (EMA) Food and Drug Administration (FDA) Musculoskeletal Transplant Foundation (MTF) Pharmaceuticals and Medical Devices Agency (PMDA) Sinai Hospital

BrainStorm Announces First Contracted U.S. Clinical Site for Phase 2 Progressive MS Study - NASDAQ.com | 4/25/2019

… CLEVELAND, Feb. 22, ( NASDAQ: BCLI ), a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, announced today Cleveland Clinic as the first U.S. clinical site contracted for a planned Phase 2 open … relapses, typically with lack of or incomplete recovery. Therapies utilizing regenerative medicine and repair approaches may offer an innovative treatment option. Autologous MSC-NTF cells are bone-marrow derived mesenchymal stem cells (MSCs) propagated and …

Cleveland Clinic, Cleveland OH

BrainStorm Announces First Contracted U.S. Clinical Site for Phase 2 Progressive MS Study - NASDAQ.com | 4/25/2019

Phase 2 Open-Label Trial of Autologous MSC-NTF Cell Therapy (NurOwn®) in Progressive MS Patients will Begin Enrollment in Early 2019 NEW YORK and CLEVELAND, Feb. 22, ( NASDAQ: BCLI ), a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, announced today Cleveland Clinic as the first U.S. clinical site contracted for a planned Phase 2 open-label, multicenter study of repeated intrathecal administration of autologous MSC …

Can Stem Cells Cure Your Chronic Pain? Experts Say Not So Fast | Yahoo News | 4/6/2019

By Liz Szabo The online video seems to promise everything an arthritis patient could want. The six-minute segment mimics a morning talk show, using a polished TV host to interview guests around a coffee table. Dr. Adam Pourcho extols the benefits of stem cells and “regenerative medicine” for healing joints without surgery. Pourcho, a sports medicine specialist, says he has used platelet injections to treat his own knee pain …

Memorial Sloan Kettering

Bayer AG buys BlueRock Therapeutics for $1 bln | PE Hub | 8/8/2019

… technology from the McEwen Stem Cell Institute at the University Health Network in Toronto and the Stem Cell Center at Memorial Sloan Kettering in New York, key management talent, intellectual property, as well as manufacturing … leadership and operations across Canada and the U.S.” “Prioritization of regenerative medicine as a new frontier for investment allowed us to develop a position in a new field with two to three years of lead …

Versant Ventures Announces Acquisition of Cell Therapy Company BlueRock Therapeutics | Business Wire | 8/8/2019

… technology from the McEwen Stem Cell Institute at the University Health Network in Toronto and the Stem Cell Center at Memorial Sloan Kettering in New York, key management talent, intellectual property, as well as manufacturing … leadership and operations across Canada and the U.S.” “Prioritization of regenerative medicine as a new frontier for investment allowed us to develop a position in a new field with two to three years of lead …

Memorial Sloan Kettering Cancer Center

Hackensack Meridian Health Opens Center for Discovery and Innovation to Support Groundbreaking Research | Markets Insider | Business Insider | 5/30/2019

… said Robert C. Garrett , CEO of Hackensack Meridian Health. The Center will be organized around three specialty areas: Institute for Regenerative Medicine, where revolutionary therapies will help diseased and damaged tissue heal itself Institute for … Cancer Consortium. Hackensack Meridian Health has formed a partnership with Memorial Sloan Kettering Cancer Center to create an exceptional uniform standard of care throughout the network’s acute care hospitals and expansive outpatient network. The center …

Hackensack Meridian

Hackensack Meridian Health opens new center focused on research and innovation | MedCity News | 6/3/2019

Hospitals Hackensack Meridian Health opens new center focused on research and innovation Called the Center for Discovery and Innovation, the facility will give researchers the support to develop therapies for diabetes, dementia, cancer, auto-immune … it will be organized around three areas: the Institute for Regenerative Medicine, the Institute for Cancer and Infectious Disease and the Institute for Multiple Myeloma. “This is about improving outcomes for patients by streamlining the

Hackensack Meridian Health Opens Center for Discovery and Innovation to Support Groundbreaking Research | Markets Insider | Business Insider | 5/30/2019

EDISON, N.J. , May 30, 2019 /PRNewswire/ – Hackensack Meridian Health is proud to announce the opening of the Center for Discovery and Innovation (CDI), a state-of-the art facility which will offer world renowned researchers … Center will be organized around three specialty areas: Institute for Regenerative Medicine, where revolutionary therapies will help diseased and damaged tissue heal itself Institute for Cancer and Infectious Disease, where new ways to treat life

Meridian Health

Hackensack Meridian Health opens new center focused on research and innovation | MedCity News | 6/3/2019

Hospitals Hackensack Meridian Health opens new center focused on research and innovation Called the Center for Discovery and Innovation, the facility will give researchers the support to develop therapies for diabetes, dementia, cancer, auto-immune … it will be organized around three areas: the Institute for Regenerative Medicine, the Institute for Cancer and Infectious Disease and the Institute for Multiple Myeloma. “This is about improving outcomes for patients by streamlining the

Hackensack Meridian Health Opens Center for Discovery and Innovation to Support Groundbreaking Research | Markets Insider | Business Insider | 5/30/2019

EDISON, N.J. , May 30, 2019 /PRNewswire/ – Hackensack Meridian Health is proud to announce the opening of the Center for Discovery and Innovation (CDI), a state-of-the art facility which will offer world renowned researchers … Center will be organized around three specialty areas: Institute for Regenerative Medicine, where revolutionary therapies will help diseased and damaged tissue heal itself Institute for Cancer and Infectious Disease, where new ways to treat life

Health Net

Bayer AG buys BlueRock Therapeutics for $1 bln | PE Hub | 8/8/2019

… over 12 months allowing the necessary time to secure foundational technology from the McEwen Stem Cell Institute at the University Health Network in Toronto and the Stem Cell Center at Memorial Sloan Kettering in New … leadership and operations across Canada and the U.S.” “Prioritization of regenerative medicine as a new frontier for investment allowed us to develop a position in a new field with two to three years of lead …

Versant Ventures Announces Acquisition of Cell Therapy Company BlueRock Therapeutics | Business Wire | 8/8/2019

… over 12 months allowing the necessary time to secure foundational technology from the McEwen Stem Cell Institute at the University Health Network in Toronto and the Stem Cell Center at Memorial Sloan Kettering in New … leadership and operations across Canada and the U.S.” “Prioritization of regenerative medicine as a new frontier for investment allowed us to develop a position in a new field with two to three years of lead …

Healthspan

Rejenevie™ Therapeutics Announces Start of Phase II Immune Restoration Treatment Clinical Trial | PR Newswire | 5/29/2019

… monitor the treatment of up to 20 patients. Phase II trial participants will receive treatment at the Okyanos Center for Regenerative Medicine in Freeport, Bahamas . During the Phase I clinical trial that concluded in February … to give aging patients an improved quality of life and healthspan,” said Mark Benerofe , President and COO, Rejenevie Therapeutics. “With promising results observed in our Phase I trial and the potential of the Phase II …

BioTime Provides Business Update Including Information on AgeX, OncoCyte and Asterias - NASDAQ.com | 4/20/2019

… early accomplishment was to sell approximately half of our shares of AgeX, which we had created to develop BioTime’s preclinical regenerative medicine assets, to Juvenescence Limited for a total of $43.2 million. Cash payments totaling … product pipeline for use in the clinic to extend human healthspan, and is seeking opportunities to form licensing and partnership agreements around its broad IP estate and proprietary technology platforms for non-core clinical applications …

Scott Gottlieb

Physicians’ Education Resource® Announces Scott Gottlieb as Keynote Speaker for the 37th Annual Chemotherapy Foundation Symposium Innovative Cancer Therapy for Tomorrow® | Business Wire | 8/8/2019

… resource for continuing medical education (CME), named public health expert and former commissioner of the Food and Drug Administration (FDA) Scott Gottlieb, M.D., as the keynote speaker for the 37th Annual Chemotherapy Foundation Symposium Innovative … modern, safe and effective oversight of gene therapies, cell-based regenerative medicines, targeted drugs and digital health devices. “With improvements in detection and monitoring, plus the discovery of new therapeutic options, we are changing the …

NEA Welcomes Scott Gottlieb, M.D., As Special Partner | PR Newswire | 5/22/2019

Scott Gottlieb , M.D., as a Special Partner on the firm’s healthcare investment team. Dr. Gottlieb was a Venture Partner at NEA from 2007 to 2017 before being appointed the 23rd Commissioner of the U.S. Food and Drug Administration (FDA), where he served from 2017 to 2019. Under Dr. Gottlieb’s leadership, the FDA advanced new policies for the safe and effective oversight of gene therapies, cell-based regenerative medicines, targeted drugs …

Mike Rice

BioLife Solutions Announces Second Quarter 2019 Financial Results | PR Newswire | 8/9/2019

… HypoThermosol ® biopreservation media and the recently acquired ThawSTAR ® automated thaw products to the high-growth cell and gene therapy market. Mike Rice , BioLife President & CEO, commented, “Throughout the second quarter, we demonstrated our ability to … of which were cell and gene therapy companies in the regenerative medicine market segment. Received 14 new cross-reference requests for our FDA master files for CryoStor and HypoThermosol. Worldwide Distributor Network Product revenue: $2.2 …

BioLife Solutions, Inc. (BLFS) CEO Mike Rice on Q2 2019 Results - Earnings Call Transcript | Seeking Alpha | 8/9/2019

… BLFS ) Q2 2019 Earnings Conference Call August 8, 2019 4:30 PM ET Company Participants Roderick de Greef - Chief Financial Officer Mike Rice - President & Chief Executive Officer Conference Call Participants George Zavoico - B. Riley FBR Operator … driven by a 33% increase and direct sales to our regenerative medicine customers and 31% growth from our distributors compared to the same period in 2018. In the total of $6.7 million, we generated revenue …

Shai Yarkoni

Cellect Biotechnology Reports Second Quarter 2019 Financial and Operating Results | PR Newswire | 8/13/2019

… Israel and we are optimistic as we move closer to commencing our first clinical trial in the U.S.,” commented Dr. Shai Yarkoni , Chief Executive Officer. “In Israel, we successfully transplanted the 9 th patient earlier … treatments and procedures in a wide variety of applications in regenerative medicine. The Company’s current clinical trial is aimed at bone marrow transplantations in cancer treatment. Forward Looking Statements This press release contains forward-looking …

Cellect Biotechnology Announces Positive Outcome From Safety Review Committee; Successfully Transplants 9th Clinical Trial Patient | PR Newswire | 8/12/2019

… partner and sharing further progress in the coming months. “We are increasingly pleased with our global clinical progress,” commented Dr. Shai Yarkoni , Chief Executive Officer. “In Israel, the DSMB’s recommendation to proceed to the final … treatments and procedures in a wide variety of applications in regenerative medicine. The Company’s current clinical trial is aimed at bone marrow transplantations in cancer treatment. Forward Looking Statements This press release contains forward-looking …

Bill Taylor

MiMedx Market Leadership Well Positioned In Light Of FDA New Guidance Document | PR Newswire | 11/17/2017

Regenerative Medicine Advanced Therapies,” Draft Guidance for Industry was published (the “RMAT Guidance”). In the final HCT/P Guidance document, FDA updated and clarified its previous draft Guidance documents regarding HCT/Ps. In summary, MiMedx views the final HCT/P Guidance document as generally beneficial to the Company, physicians and patients. Bill Taylor , President and Chief Operating Officer, commented, “While there are a few items that are not consistent with …

Roderick de Greef

BioLife Solutions Announces Second Quarter 2019 Financial Results | PR Newswire | 8/9/2019

… media customers and 39 new automated thaw products customers, most of which were cell and gene therapy companies in the regenerative medicine market segment. Received 14 new cross-reference requests for our FDA master files … acquisition of Astero Bio Corporation, which closed in early April. Roderick de Greef , BioLife Chief Financial Officer, remarked, “In addition to successfully integrating Astero’s operations during the second quarter, our financial results at all levels …

BioLife Solutions Announces Second Quarter 2019 Financial Results - NASDAQ.com | 8/9/2019

… media customers and 39 new automated thaw products customers, most of which were cell and gene therapy companies in the regenerative medicine market segment. Received 14 new cross-reference requests for our FDA master files … acquisition of Astero Bio Corporation, which closed in early April. Roderick de Greef, BioLife Chief Financial Officer, remarked, “In addition to successfully integrating Astero’s operations during the second quarter, our financial results at all levels …

Jerrell Shelton

Cryoport Revenue Grows 83% for Second Quarter 2019 | PR Newswire | 8/9/2019

… month period ended June 30, 2019 , an increase of 83% compared with the same period in the prior year,” stated Jerrell Shelton , Chief Executive Officer of Cryoport. “Revenue from our commercial agreements supporting Gilead’s YESCARTA … of which 52 are currently in Phase III. As the regenerative medicine market continues to gain pace, we expect to continue to grow the number of clinical trials we support, which, together with the increasing …

Cryoport and EVERSANA Form Strategic Alliance to Accelerate Regenerative Medicine Supply Chain | Markets Insider | Business Insider | 7/11/2019

… PRNewswire/ – Cryoport, Inc. (NASDAQ: CYRX) (NASDAQ: CYRXW) and EVERSANA™ have announced a strategic alliance to further create a fully integrated regenerative medicine supply chain solution. The alliance will be designed to leverage EVERSANA’s position as … of our companies and provide synergistic value to our clients.” Jerrell Shelton , Cryoport CEO added, “Through our alliance, Cryoport will provide EVERSANA and its clients with our full suite of logistics solutions under our ‘ powered …

Ronald G. Victor

Significant Improvements Reported in Duchenne Muscular Dystrophy Patients Treated with Capricor’s Investigational Cell Therapy | PR Newswire | 11/15/2017

Significant Improvements Reported in Duchenne Muscular Dystrophy Patients Treated with Capricor’s Investigational Cell Therapy Dr. Ronald G. Victor Presents 12-Month Results of HOPE Clinical Trial at AHA Late-Breaking SessionCompany to Host Conference Call … trial was funded in part by the California Institute for Regenerative Medicine. About Duchenne Muscular Dystrophy Duchenne muscular dystrophy is a devastating genetic disorder that causes muscle degeneration and leads to death, generally before the

Significant Improvements Reported in Duchenne Muscular Dystrophy Patients Treated with Capricor’s | PR Newswire | 11/15/2017

… with CAP-1002, the lead investigational therapy under development at Capricor Therapeutics (NASDAQ: CAPR ). These findings were reported today by Ronald G. Victor , M.D. at a Late-Breaking Science session of the American Heart Association … trial was funded in part by the California Institute for Regenerative Medicine. About Duchenne Muscular Dystrophy Duchenne muscular dystrophy is a devastating genetic disorder that causes muscle degeneration and leads to death, generally before the …

Linda Marbán

Capricor Therapeutics Reports Third Quarter 2017 Financial Results and Provides Update on Duchenne Muscular Dystrophy Development Program | CNBC | 11/9/2017

… are actively building our organization in key functional areas as we continue to advance this candidate toward potential registration,” said Linda Marbán, Ph.D., president and chief executive officer. “In the near-term, we look forward … trials were funded in part by the California Institute for Regenerative Medicine. Cautionary Note Regarding Forward-Looking Statements Statements in this press release regarding the efficacy, safety, and intended utilization of Capricor’s product candidates; the …

Greg Bailey

‘Extraordinary’ Breakthroughs In Anti-Aging Research ‘Will Happen Faster Than People Think’ | Forbes | 8/26/2019

People 50 and older have a lot to look forward to, according to Juvenescence’s Greg Bailey—mainly that we won’t be aging as fast or poorly as our parents. “Science fiction has become science,” said … of Health (NIH) and conducted at UPIT’s McGowan Institute for Regenerative Medicine . Michael Hufford, PhD, Chief Executive Officer of LyGenesis, said the technology could address the problem of the imbalance between organ supply and demand

AgeX Therapeutics, Inc. Reports Second Quarter 2019 Financial Results and Provides Business Update | Business & Finance | heraldchronicle.com | Business Wire | 8/14/2019

… us as we work toward our goal of becoming a leading biotechnology company in cellular therapies and human aging,” commented Greg Bailey, M.D., Chairperson of the Board of Directors. “Our commitment to this goal is … Dr. West at Undoing Aging in Berlin, Germany, on AgeX’s regenerative medicine product development. At the conference, Dr. West also presented data relating to the central molecular clockwork mechanisms that AgeX is targeting with its …

Yehiel Tal

CollPlant Biotechnologies Raising $5.5 Million | PR Newswire | 9/3/2019

REHOVOT, Israel , Sept. 3, CollPlant (NASDAQ: CLGN ) (the “Company”), a regenerative medicine company, announced it has entered into definitive agreements for up to $6.5 million funding in convertible loans. The capital raise is by way … medical aesthetics and 3D bioprinting of tissues and organs,” stated Yehiel Tal , the Chief Executive Officer of CollPlant. “We are now focused on facilitating our development programs of dermal fillers and regenerative breast implants. Our

CollPlant Reports First Quarter 2019 Financial Results and Provides Business Update | PR Newswire | 5/30/2019

REHOVOT, Israel , May 30, CollPlant (NASDAQ: CLGN ), a regenerative medicine company, today announced financial results for the first quarter ended March 31, 2019 and provided an update on the Company’s business developments. Certain metrics, including … of transplantable lungs for patients with serious medical conditions,” said Yehiel Tal , CollPlant’s Chief Executive Officer. “In the medical aesthetics market, we are moving forward with the development of a new dermal filler product line